Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label Alzheimer. Show all posts
Showing posts with label Alzheimer. Show all posts

Wednesday, May 29, 2013

Deep Brain Stimulation: Evidence Based Science or Wishful Thinking?

Deep Brain Stimulation: Evidence Based Science or Wishful Thinking?



By Natalie Timoshin, Managing Editor | May 28, 2013



I have a friend whose nephew received a diagnosis of late stage cancer about 9 months ago—everyone thought (but didn’t say) his chances for survival were slim. After stem cell transplantation, he’s just marked 100 days of being cancer free.

Cancer outcomes like this make me optimistic for the future. Deep brain stimulation (DBS) might be another reason to feel optimistic about the future.

One of my favorite sites on the internet is Ted Talks. I don’t spend a lot of time on the internet, but I do have a few favorites (eg, New York Times, Psychiatric Times, the National Gallery of Art), and Ted Talks tops this list. The topics are varied and I learn something new every time: I recently learned how to tie my shoelaces so that they don’t untie and had my future brightened by Andres Lozano, MD, PhD, who talked about Parkinson, depression, and ways that their processes might be turned off.

Because of new imaging techniques and advances in our understanding of neurophysiology, neurological and psychiatric disorders are increasingly being recognized as disorders of circuit functions in the brain. Using techniques such as DBS, neurosurgeons are able to pinpoint malfunctioning circuits and to recalibrate them. DBS is very precise—the electrode is inserted through the skull and into any area of the brain to deliver electricity.

Dr Lozano is chief of neurosurgery at the University of Toronto, where he and his team are studying the use of DBS to turn brain circuits on and off, depending on the circuits’ role in certain disorders (eg, movement, mood, memory). In his presentation on Ted Talk, Lozano describes the case of a little boy with dystonia who is no longer able to stand or walk and whose prognosis is dismal—he will be progressively more disabled and his chances of survival are nil. Dr Lozano and his team used DBS to suppress the circuits in his brain responsible for movement. Three months later the boy is walking. As a young adult he is living a normal life and going to university.

Both pharmacological and psychotherapeutic modalities are used to treat MDD, yet 10% to 20% of patients with depression do not respond to treatment. PET scans have shown that areas of the brain responsible for motivation, drive, and decision making are impaired in patients with severe depression, and the sadness center is overactive. After six months of continuous DBS, the sadness center is turned off, and the circuits responsible for motivation, drive, and decision making have made a comeback.

Similar positive results were seen when DBS was used in patients with early Alzheimer disease. Healthy brains use 20% of the body’s supply of glucose—as Alzheimer disease progresses, glucose utilization shuts down. Dr Lozano and his team wanted to know if this “power failure” could be reversed. They placed DBS electrodes in the Fornix area of the brain and looked at what happened to glucose consumption. After one month, areas of the brain that had stopped using glucose had resumed consumption. The implications seem to be that not only can DBS modify symptoms but that the technique can help repair damaged areas of the brain as well.

Is DBS evidence-based science or wishful thinking? What do you make of the different brain stimulating techniques? Is there reason for my optimism? Can I continue to believe that my golden years will not be plagued by memory loss and cognitive decline?

Oh, my friend’s nephew . . . he celebrated by getting engaged!

http://www.psychiatrictimes.com/display/article/10168/2144438

Tuesday, May 14, 2013

1.Deep brain stimulation: a fix when the drugs don’t work



  1. 5mz7jv4q-1368163791
    Implanted electrodes can alleviate symptoms of Parkinson’s and Alzheimer’s, and help treat addiction. Wikimedia Commons

    Neurological disorders can have a devastating impact on the lives of sufferers and their families.



  2. Drug treatments are often ineffective in these disorders. But what if there was a way to simply switch off a devastating tremor, or boost a fading memory?


  3. Recent advances using Deep Brain Stimulation (DBS) in selective brain regions have provided therapeutic benefits and have allowed those affected by these neurological disorders freedom from their symptoms, in absence of an existing cure.

    A pacemaker for the brain

    Artificial cardiac pacemakers are typically associated with controlling and resynchronising heartbeats by electrical stimulation of the heart muscle.
    Schematic of deep brain stimulation. stutteringmedia
    Click to enlarge

    In a similar manner, DBS sends electrical impulses to specific parts of the brain that control discrete functions. This stimulation evokes control over the neural activity within these regions.
    Prior to switching on the electrical stimulation, electrodes are surgically implanted within precise brain regions to control a specific function.


  4. The neurosurgery is conducted under local anaesthetic to maintain consciousness in the patient. This ensures that the electrode does not damage critical brain regions.



  5. Following recovery from surgery the electrodes are activated and the current calibrated by a neurologist to determine the optimal stimulation parameters.


  6. The patient can then control whether the electrodes are on or off by a remote battery-powered device.


  7. Deep Brain Stimulation surgery.

    Turning off tremors

    Perhaps the most documented success of DBS is in the control of tremors and motor coordination in Parkinson’s disease.


  8. This is caused by the degeneration of neurons in an area of the brain called the substantia nigra. These neurons secrete the neurotransmitter dopamine.
    Basal ganglia circuits, including substantia nigra. Wikimedia Commons
    Click to enlarge

    Deterioration of these neurons reduces the amount of dopamine available to be released in a brain area involved in movement, the basal ganglia.


  9. Drug therapy for Parkinson’s disease involves the use of levodopa (L-DOPA), a form of dopamine that can cross the blood brain barrier and then be synthesised into dopamine.


  10. The administration of L-DOPA temporarily reduces the motor symptoms by increasing dopamine concentrations in the brain. However, side effects of this treatment include nausea and disordered movement.


  11. DBS has been shown to provide relief from the motoric symptoms of Parkinson’s disease and essential tremors.



  12. These are regions innervated by the deteriorating substantia nigra, therefore the DBS boosts stimulation to these areas.


  13. Patients can then switch on the electrodes, stimulating these brain regions to enhance control of movement and diminish tremors.

    Restoring fading memories

    Recently, DBS has been used to diminish memory deficits associated with Alzheimer’s disease, a progressive and terminal form of dementia.
    British author Terry Pratchett has been diagnosed with Alzheimer’s Disease. Bolt of Blue

    The pathologies associated with Alzheimer’s disease involve the formation of amyloid plaques and neurofibrillary tangles within the brain leading to dysfunction and death of neurons.


  14. Brain regions primarily affected include the temporal lobes, containing important memory structures including the hippocampus.


  15. Recent clinical trials with DBS involve the implantation of electrodes within the fornix – a structure connecting the left and right hippocampi together.


  16. By stimulating neural activity within the hippocampi via the fornix, memory deficits associated with Alzheimer’s disease can be improved, enhancing the daily functioning of patients and slowing the progression of cognitive decline.

    Deactivating addiction

    Another use of DBS is in the treatment of substance abuse and drug addiction. Substance-related addictions constitute the most frequently occurring psychiatric disease category and patients are prone to relapse following rehabilitative treatment.



  17. Understanding of the reward systems affected in addiction has created a range of treatment options that directly target dysregulated brain circuits in order to normalise functionality.


  18. One of the key reward regions in the brain is the nucleus accumbens and this has been used as a DBS target to control addiction.


  19. Translational animal research has indicated that stimulation of the nucleus accumbens decreases drug seeking in models of addiction. Clinical studies have shown improved abstinence in both heroin addicts and alcoholics.
    Diagram of a rat self-administering morphine. Wikimedia Commons
    Click to enlarge

    Studies have extended the use of DBS to potentially restore control of maladaptive eating behaviours such as compulsive binge eating.


  20. In a recent study, binge eating of a high fat food in mice was decreased by DBS of the nucleus accumbens. This is the first study demonstrating that DBS can control maladaptive eating behaviours and may be a potential therapeutic tool in obesity.


  21. Despite its therapeutic use for more than a decade, the neural mechanism of DBS is still not yet fully understood.


  22. The remedial effect is proposed to involve modulation of the dopamine system – and this seems particularly relevant in the context of Parkinson’s disease and addiction.


  23. DBS potentially has effects on the functional activity of other interconnected brain systems. While it can provide therapeutic relief from symptoms of neurological diseases, it does not treat the underlying pathology.


  24. But it provides both effective and rapid intervention from the effects of debilitating illnesses, restoring activity in deteriorating brain regions and aids understanding of the brain circuits involved in these disorders.

Sunday, May 6, 2012

When illness makes a spouse a stranger

When illness makes a spouse a stranger

Rare ailment, frontotemporal dementia, has no cure or treatment    

Video: NYT: When illness makes a spouse a stranger

Béatrice de Géa for The New York
Michael French, 71, of Manhattan, has a rare brain disease, frontotemporal dementia, that strips away personality and language. His wife, Ruth, has struggled to care for him.
           
By
updated 5/6/2012 2:33:11 PM ET2012-05-06T18:33:11
He threw away tax documents, got a ticket for trying to pass an ambulance and bought stock in companies that were obviously in trouble. Once a good cook, he burned every pot in the house. He became withdrawn and silent, and no longer spoke to his wife over dinner. That same failure to communicate got him fired from his job at a consulting firm.

By 2006, Michael French — a smart, good-natured, hardworking man — had become someone his wife, Ruth, felt she hardly knew. Infuriated, she considered divorce.

But in 2007, she found out what was wrong.

“I cried,” Mrs. French said. “I can’t tell you how much I cried, and how much I apologized to him for every perceived wrong or misunderstanding.”

Mr. French, now 71, has frontotemporal dementia — a little-known, poorly understood and frequently misdiagnosed group of brain diseases that eat away at personality and language. Although it was first recognized more than 100 years ago, there is still no cure or treatment, and patients survive an average of only eight years after the diagnosis.

But recently, researchers have been making important discoveries about the biochemical and genetic defects that cause some forms of the disease. And for the first time, they have identified drugs that may be able to treat one of those defects, the buildup of abnormal proteins in the brain. Tests in people, the first ever such drug trials in this disease, could begin as soon as early next year at the University of California, San Francisco.

“There’s really been an explosion related to the biology,” said Dr. Bruce L. Miller, a professor of neurology and psychiatry there. “I think at least some subtypes of frontotemporal dementia will be the first neurodegenerative diseases we find a cure for.”

This disease is different from Alzheimer’s, the most common form of dementia. But it is perhaps even more devastating, because it strikes younger people, progresses faster and, unlike Alzheimer’s, does not attack memory at first but begins with silence, apathy or bizarre personality changes. It is thought to afflict at least 50,000 to 60,000 people in the United States.

The scientific findings in frontotemporal dementia may also reshape thinking about the fundamental flaws involved in Alzheimer’s disease.

“I think the way dementia is going in general now is to realize there are many different subtypes,” Dr. Miller said, adding that what is now labeled Alzheimer’s disease may actually turn out to include hundreds of different illnesses.

Dementia is a formidable adversary, and the history of efforts to treat Alzheimer’s has to temper any excitement about potential medicines for frontotemporal disease. The drugs for Alzheimer’s have been a disappointment, with just temporary effects on symptoms at best.

But even if treatments or cures for frontotemporal dementia do emerge, they will almost certainly come too late for people with advanced cases, like Mr. French or Richard Rainwater, a billionaire investor who learned in 2009 that he had progressive supranuclear palsy, which some consider a form of frontotemporal dementia. Mr. Rainwater and his family have donated more than $20 million to a research consortium, but given that he has a rapidly progressive form, any advances from the consortium may be more likely to help others than to save him.

Looking for Answers

Looking back, Mrs. French, who is 66 and lives in Manhattan, recalled episodes of odd behavior over the years and realized that her husband’s mind had probably begun to slip while he was in his 50s, at least a decade before the disease was diagnosed. He had always changed jobs a lot. At the time she took it as a sign of a stubborn personality, not of illness — and it is still not clear which it was. He always wanted to do things his own way, and that did not sit well with some bosses.

“I thought it was just Michael being Michael,” she said.

A friend described Mr. French as being unable to read the tea leaves, oblivious of corporate politics. At one point Mrs. French even bought him a self-help book. But he never changed.

And he always found another job, better than the one before. But things went downhill in 2006.

“His immediate boss was so frustrated by him that she called up, and we were at the dinner table, and I could hear her screaming,” Mrs. French said.

He was fired, and this time he did not find another job. At 66, he retired.

Soon after, because he had trouble speaking, he consulted a neurologist. When they got the diagnosis, Mrs. French asked the doctor, “How do we treat it?”

“It’s brain atrophy,” he replied.

Her thoughts of divorce evaporated. Instead, she told her husband: “Whatever happens, we will go through this together. I will be there.”

From then on, the silence at the dinner table no longer troubled her. It did not seem personal anymore. He was not refusing to talk; he simply could not. Her anger melted into sadness.

But sometimes she still blew her top. Once, she came home and found him at the stove, seemingly unaware that his oven mitt was smoldering.

“I actually hit him a couple times out of frustration,” she said. What made her lose control, she said, was a toxic mix of frustration and fear — fear of what was happening to him, and fear that she would not know what to do, how to help. No amount of information from his doctors could put her at ease.

“They can tell you everything that’s ever happened to anyone, but they can’t tell you what’s going to happen to you,” she said.
The last five years have been wrenching and often lonely. Michael was the love of her life. When she married him, her sister asked, “How does it feel to hit the jackpot?” In more than 30 years of marriage, she never heard him say an unkind word about anyone. He was an engineer, lectured at conventions, did volunteer work, belonged to a history book club, ran marathons. Now he can no longer speak, read, write or walk.

If there is comfort anywhere for Mrs. French, it is in knowing one thing: she has kept her promise to be there.

The Science

Frontotemporal dementia, also called frontotemporal degeneration or Pick’s disease, refers to a group of diseases that destroy nerve centers in the frontal and temporal lobes — the home of decision-making, emotion, judgment, behavior and language. Some forms of the disease also cause movement disorders.

Most cases occur sporadically, in people with no family history of the illness — like Michael French — but a small percentage are inherited.

Patients generally receive from one to four misdiagnoses, and it may take years to finally get the right answer. Mistaken diagnoses can include Alzheimer’s disease, stroke, midlife crisis or psychiatric illnesses like depression, bipolar disorder, post-traumatic stress or anxiety. Many relatives of patients say doctors dismiss their reports of personality change. But it is real.

"They totally break down in their ability to connect with other people and care about them,” Dr. Miller said.

There are eight subtypes of frontotemporal degeneration, sorted by the symptoms they cause. Some affect behavior. Others, grouped under the heading primary progressive aphasia, affect language. Still others affect movement, leading to disorders that resemble Parkinson’s or Lou Gehrig’s disease (also called amyotrophic lateral sclerosis or A.L.S.).

But patients may match more than one category, and the subtype may change as the disease progresses.

“I see a lot who don’t present like the textbook,” said Dr. Edward Huey, an assistant professor of psychiatry and neurology at Columbia University Medical Center.

In most patients, MRI and other scans reveal shrinkage in the frontal and temporal lobes, sometimes to a shocking degree.

“If I showed you more extreme cases, you could read it from across the room,” Dr. Huey said.
He said researchers were using imaging to find out if specific symptoms could be mapped to atrophy in certain spots.

“The frontal lobes are sort of the last frontier in the brain,” Dr. Huey said, adding that the losses these patients suffer are helping researchers understand more about what the frontal lobes do. As the brain atrophy progresses, Dr. Huey said, patients “have pieces of psychiatric syndromes, but not the whole syndrome.” For instance, they have compulsions, but not the usual accompaniment, obsessions. So they may wash their hands over and over again, but not in a worried or anxious way. Some lose their inhibitions and moral judgment. Shoplifting is not uncommon. Many have the apathy and social disconnection that usually go with depression, but they do not feel depressed.

“They’re not down, but they just don’t enjoy things as much as they used to,” Dr. Huey said. “There appears to be a dysfunction in the reward circuit, where activities that were rewarding and pleasurable no longer seem to be. These patients lose themselves.”

Many seem to go on endless eating binges and gain weight. It is not clear why — whether they are actually hungry or whether the eating is just another compulsion. Some people with the illness shower repeatedly or check the mail 100 times a day. One possible reason, Dr. Huey said, is that “the part of the brain that tells you, ‘No, that task is done,’ is gone.” Some patients collect things — by the hundreds. A few have had bursts of creativity in music or painting, possibly because other brain regions come to the fore as the frontal lobes wither.

A Way of Life Cut Short

Long before her husband became ill, Mrs. French had a successful career in sales and marketing for textile companies and ultimately became a vice president at Liberty of London. But she gave it up in 1991 to do something she loved: teaching English as a second language to adults. She was doing that work when his condition was diagnosed.

One day, in a moment of inspiration, she asked her students if they knew the traditional wedding vows in English. She began to recite them. At “for better, for worse,” she choked up. Struggling to keep her composure, she quickly finished and moved on to another subject.

After teaching, she would walk home through Central Park, and in the early days of his illness Mr. French would often meet her halfway. She would see him heading toward her, smiling and strikingly handsome. “When I look at Michael, that’s what I see, that’s who he will always be to me.”

In 2007, Mrs. French joined a support group for caregivers of people with frontotemporal dementia. Jill Goldman, a genetic counselor at Columbia University Medical Center, said she started the group because patients’ relatives felt that they did not fit in at Alzheimer’s groups; their loved ones were younger and often had bizarre behaviors that were nothing like Alzheimer’s.

“One of the things that goes first is insight,” Ms. Goldman said. “‘There’s nothing wrong with me. Why can’t I do what I want to do?’ ”

Members of the group tell of loved ones who hug strangers, who fly into terrifying rages and hit family members and health aides, or who pass their days in silence cutting up newspapers or watching television. Patients are easily taken in by financial scams that can cost families thousands of dollars. Often, apathy sets in, and people once devoted to their families lose interest in everyone, even their own children.

“My son and I look out the window and see my wife out there, stepping on leaves, and we start to cry,” one member said.

Some have struggled with uncertain diagnoses because patients have symptoms of both Alzheimer’s and frontotemporal disease. One wife described trips to multiple doctors and inconclusive reports on PET scans and spinal taps. Should she have taken her husband to the Mayo Clinic? She agonized over the idea that he might have some illness other than frontotemporal dementia or Alzheimer’s, something treatable, and that there might be some way to rescue him, to bring him back.

Another said her husband, a judge who had always been mild-mannered and modest, turned boastful and began talking to strangers in the street, making jokes at the wrong time and falling for scams.
“He salutes every flag, closes every gate, kisses every hand,” she said.

Riding the bus in Manhattan, he will loudly announce, “I haven’t killed anybody lately.” Not infrequently it gets him a seat. He can turn violent and has struck a health aide with his cane.

“He’s just mean and nasty,” his wife said. “He was such a wonderful man. He’s not a person anymore.”

Ms. Goldman provides stacks of business-size cards that spouses can hand out to strangers in awkward situations.

“My husband has a terminal brain disease called frontotemporal dementia,” the cards read. “Thank you for your understanding.”

Many find that friends and family pull away. Nearly all grapple with whether and when to take away car keys, give drugs to blunt aggression, hire a health aide or put the patient in a nursing home. One group member said, “The doctor told me, ‘You’re taking good care of him, he’ll live a long time,’ and I said, ‘Why is that a good thing?’ ”

Patients are hard to care for at home, and those who are young, strong and aggressive are sometimes kicked out of nursing homes because they are seen as posing a physical threat. But employers do not necessarily sympathize with relatives called out of work in the middle of the day because a patient has punched or shoved someone at the nursing home.

“My boss says, ‘You just have to deal with this better,’ ” one group member said.

Another group member, a professor of psychotherapy and mental health counseling, said she quit her job at the height of her career to take care of her partner and after a few years became suicidal.
“Being a caregiver in this disease is a grieving process,” she said, “while the person is still alive.”

Easing the Burden

Ruth and Michael French managed on their own until May 2009, when he fell down a flight of stairs in their apartment building while she was at work. He fractured his skull and came home in a wheelchair, so weak and frail that she hired an aide to help take care of him.

Mrs. French is fine-boned and thin, and as her husband grew weaker, the physical demands on her became daunting. Streets she had thought flat revealed themselves to be hills once she found herself trying to push a 140-pound man in a wheelchair. Potholes yawned like chasms. One night at home, after helping him clean his teeth, she turned to put the toothbrush away, and in that moment he fell into the bathtub. She was barely able to pull him up.

“I said, ‘Michael, now we’re at the point where we’re both at risk,’ ” she recalled.

She injured her wrist, developed a stomach ulcer and lost so much weight that people worried about her. Mr. French became incontinent, and she would sometimes wake up in a pool of his urine. The health aide hurt her back lifting him.

“I heard myself say one day, ‘I would never want anybody to do for me what I’m doing for Michael,’ ” Mrs. French said.

She had hoped to keep him at home until the end but knew it might not be possible. “This thing is going to kill both of us, and I don’t know who’s going first,” she told him.

In one way, she had an easier time than many other caregivers. Her husband never turned hostile. He retained a sweetness, and an acceptance of his illness that she found inspiring.

At one point, worried about finances, she considered laying off the aide and taking care of Michael alone. When members of her support group worried that the stress would kill her, she told them, “That might not be so bad.”

At Ms. Goldman’s urging, she saw a psychotherapist. He recommended medications to calm her. She filled the prescription but threw the pills away.

“I kind of feel that having gone through the anxiety and the worry is what let me get to the other side,” Mrs. French said.

While Mr. French was still well enough, they had discussed the possibility of a nursing home. So when the time came, it was not really a surprise.

“He knew it was something I didn’t want to do, because every time we spoke about it I would cry,” Mrs. French said. “When I told him that I had made arrangements, he said — and this is a man who can’t speak, so he had to muster every bit of energy he could — he said, ‘You did the best you could.’ ”

In April last year, Mrs. French placed her husband in a nursing home in Manhattan. Along with her sadness came feelings of relief and freedom. Soon after he was settled, she went out to dinner with friends for the first time in two years.

“At times, I ache for him to be back in the apartment,” she said. “But I ache for him to be back as him.”

She said that long after he ceased speaking, he continues to understand what she says.
“I remember asking his neurologist, ‘Will he know me?’ ” Mrs. French said. “And he said, ‘Oh, he’ll always know you. He might not be able to express it in a way that will be familiar to you or that you’ll like, but he’ll always know you.’ ”

She wondered what longings might drive her husband’s dreams:

“I asked him, ‘Do you talk in your dreams?’ and he said, ‘Yes.’ And I asked him, ‘Do you dream about me?’ And he said, ‘Yes.’ ”

She has had time to think about mortality, his and her own.

“Death to me has always been a wake-up call to live,” she said. “This is the endgame. Sometimes I get upset because I don’t think I have enough money, and sometimes I get upset because I think I do. You don’t necessarily want to live too long, but neither do you want to die.”

On most days, she spends several hours at the nursing home with her husband. She shaves him and sometimes climbs into bed with him to hold him and to nap together.

“Where do you carry my heart?” she asks him, referring to a poem they love by E. E. Cummings.
He smiles and pats his chest.

i carry your heart with me(i carry it in
my heart)i am never without it(anywhere
i go you go,my dear;and whatever is done
by only me is your doing,my darling)
i fear no fate(for you are my fate,my sweet)i want
no world(for beautiful you are my world,my true)

Excerpt reprinted from “Complete Poems: 1904-1962” by E. E. Cummings, ed. George J. Firmage. With the permission of the Liveright Publishing Corporation.
This story, "When Illness Makes a Spouse a Stranger," was originally published in The New York Times.

http://today.msnbc.msn.com/id/47314169/ns/today-today_health/t/when-illness-makes-spouse-stranger/

Wednesday, March 7, 2012

Brain stimulator helps slow man's Alzheimer's disease

Brain stimulator helps slow man's Alzheimer's disease

For a man diagnosed with Alzheimer's disease six years ago, Robert Linton, is doing exceedingly well. Instead of struggling with becoming more forgetful, he is feeling great. And he believes it's all because of an experimental treatment that has slowed his disease.For a man diagnosed with Alzheimer's disease six years ago, Robert Linton, is doing exceedingly well. Instead of struggling with becoming more forgetful, he is feeling great. And he believes it's all because of an experimental treatment that has slowed his disease.

In this image Robert Linton is seen. Linton is one of only six Alzheimer's patients in the world who has had an electrical stimulator implanted into his brain that appears to be keeping his memory healthy.In this image Robert Linton is seen. Linton is one of only six Alzheimer's patients in the world who has had an electrical stimulator implanted into his brain that appears to be keeping his memory healthy.
Dr. Andres M. Lozano, left, sits next to patient Robert Linton as he demonstrates how electrodes are used to slow the progression of Alzheimer's disease through deep brain stimulation during a press conference at Toronto Western Hospital Wednesday, Aug. 4, 2010. (Darren Calabrese / THE CANADIAN PRESS)Dr. Andres M. Lozano, left, sits next to patient Robert Linton as he demonstrates how electrodes are used to slow the progression of Alzheimer's disease through deep brain stimulation during a press conference at Toronto Western Hospital Wednesday, Aug. 4, 2010. (Darren Calabrese / THE CANADIAN PRESS)
Updated: Tue Mar. 06 2012 20:19:03

CTVNews.ca Staff

For a man diagnosed with Alzheimer's disease six years ago, Robert Linton, is doing exceedingly well. Instead of struggling with becoming more forgetful, he is feeling great. And he believes it's all because of an experimental treatment that has slowed his disease.

Linton is one of only six Alzheimer's patients in the world who has had an electrical stimulator implanted into his brain that appears to be keeping his memory healthy.

Robert, 66, is doing great though most with his brain disease might have been in a nursing home so many years after diagnosis. He still drives and has little trouble recalling the words he needs to complete a crossword puzzle.

Linton credits the device in his brain for keeping his memory healthy.

"I think it is the answer to Alzheimer's -- 100 per cent," he says.
  • CTVNews.ca will host a live web chat Wednesday at 12 p.m. ET with Dr. Andres Lozano, neurosurgeon and scientist at the Krembil Neuroscience Centre, Toronto Western Hospital, along with fellow researcher Dr. David Tang-Wai, a neurologist in the Memory Clinic at the Krembil Neuroscience Centre, whose research focuses on Alzheimer's disease.
Four years ago, doctors at the Krembil Neuroscience Unit at Toronto Western Hospital drilled holes in Linton's skull and implanted two electrodes deep into his brain. The electrodes send out electrical bursts into the regions of Linton's brain that govern memories-- an area usually damaged by Alzheimer's.

The system is powered by a pacemaker-sized battery pack that sits under the skin of Linton's upper chest.

Neurosurgeon Dr. Andres Lozano implanted similar devices in five other patients as part of a study to determine whether brain stimulation can slow Alzheimer's progression. The research team has tracked the patients to see how their disease has progressed.

After two years, the team had the patients undergo a standard cognitive functioning test, known as the "mini-mental." In three of the patients, their test scores declined, suggesting the treatment hadn't worked. In two patients, their test scores remained the same, suggesting their disease has stabilized rather than worsened as one would expect.

In Linton's case, many of his Alzheimer's symptoms, such as his poor memory and problem solving skills, have actually improved -- much to the delight of doctors

"Rather than seeing a decline in his cognition and memory, we saw that he improved. That is exciting because it suggests maybe we are having an impact," says Dr. Lozano.

Linton himself has noticed it's easier to recall things since he had the stimulator implanted.

"If I want to remember something, I relax for a bit and it pops in," he says.

Linton's wife Barb says her husband's Alzheimer's isn't completely gone, but it isn't getting worse either.

"Whether (the treatment) slowed it or stopped it... we can only ask what would have happened had we not gone ahead with it," she says.

Robert is convinced the brain stimulator can take all the credit.

"I would have gradually declined and ended up in a nursing home. Yes, I think I see brighter worlds out there because of the operation," he says.

Doctors also performed MRI exams on the brains of the six patients. In most Alzheimer's patients, the areas of the brain controlling memory tend to shrink over time. But in Robert and another patient with early stage disease, the electrical stimulation appeared to have made the memory area of their brains grow.

It was a finding that surprised even Dr. Lozano.

"We are thrilled he is doing so well and we are trying to understand why is it he is doing so well," says Dr. Lozano.

Lozano speculates that the best candidates for the treatment may be those, like Linton, who are in the earliest stages of Alzheimer's disease. That way, the treatment can intervene before too much brain tissue has been lost to the disease.

It took Lozano's team 18 months to get ethics approval to conduct the small, Phase 1 trial of deep brain stimulation in Alzheimer's patients. The findings from that phase were published in the journal Annals of Neurology.

Lozano's team would now like to move to larger Phase 2 and Phase 3 trials, to test the technique in 40 to 50 patients, but they are still waiting for approval. Each phase of those trials would likely take about three years each, meaning wider availability of the treatment is likely still many years away -- assuming all goes well in those studies.

There are also questions about the costs of the procedure, and whether it's a feasible treatment for the broader population.

While there's much more work to be done, this research is an important first step for learning how to slow a disease with so few treatment options.

With a report from CTV's medical specialist Avis Favaro and producer Elizabeth St. Philip

http://edmonton.ctv.ca/servlet/an/local/CTVNews/20120306/alzheimers-deep-brain-stimulation-120306/20120306/?hub=EdmontonHome

Wednesday, November 3, 2010

[Perioperative considerations in vagal nerve stimulator implantation].

Rev Esp Anestesiol Reanim. 2010 Aug-Sep;57(7):431-8.

[Perioperative considerations in vagal nerve stimulator implantation].

[Article in Spanish]
Servicio de Anestesiología y Reanimación, Hospital de Cruces, Baracaldo,. Bizkaia. fib96@euskalnet.net

Abstract

Vagal nerve stimulation has become an a important tool in the treatment of refractory epilepsy, which continues to be the main indication for this technique. Other therapeutic indications are emerging, however, and vagal nerve stimulation has now been approved for major depression. Additional possible uses under study include morbid obesity, Alzheimer disease, chronic pain syndromes, and certain neuropsychologic disorders. This review considers perioperative aspects relevant to using this therapeutic procedure with a view to facilitating better and more integrated management of its application.
PMID: 20857639 [PubMed - indexed for MEDLINE]